Social confidence, social inclusion, social networks, or personalised quality of life ‐ not reported · patients with antipsychotic‐induced tardive dyskinesia
1 finding from 1 review
Overall survival† · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies leads to lower overall survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.42 [0.37, 0.48]
418 participants
High
Overall survival† · people with cutaneous melanoma
BRAF inhibitors leads to lower overall survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.4 [0.28, 0.57]
925 participants
High
Progression‐free survival · people with cutaneous melanoma
BRAF inhibitors leads to lower progression‐free survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.27 [0.21, 0.34]
925 participants
High
Tumour response · people with cutaneous melanoma
BRAF inhibitors leads to higher tumour response compared with chemotherapy (high certainty).
1 finding from 1 review
RR 6.78 [4.84, 9.49]
925 participants
High
Progression‐free survival · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
1 finding from 1 review
HR 0.49 [0.39, 0.61]
957 participants
Moderate
Toxicity (≥ G3) · people with cutaneous melanoma
BRAF inhibitors showed no clear difference in toxicity (≥ G3) compared with chemotherapy (low certainty).
1 finding from 1 review
RR 1.27 [0.48, 3.33]
408 participants
Low
Overall survival† · people with cutaneous melanoma
MEK inhibitors showed no clear difference in overall survival† compared with chemotherapy (low certainty).
1 finding from 1 review
HR 0.85 [0.58, 1.25]
496 participants
Low
Progression‐free survival · people with cutaneous melanoma
MEK inhibitors probably leads to lower progression‐free survival† compared with chemotherapy (moderate certainty).
1 finding from 1 review
HR 0.58 [0.42, 0.8]
496 participants
Moderate
Tumour response · people with cutaneous melanoma
MEK inhibitors leads to higher tumour response compared with chemotherapy (high certainty).
1 finding from 1 review
RR 2.01 [1.35, 2.99]
496 participants
High
Toxicity (≥ G3) · people with cutaneous melanoma
MEK inhibitors probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
1 finding from 1 review
RR 1.61 [1.08, 2.41]
91 participants
Moderate
Tumour response · people with cutaneous melanoma
Anti‐PD1 monoclonal antibodies leads to higher tumour response compared with chemotherapy (high certainty).
1 finding from 1 review
RR 3.42 [2.38, 4.92]
1367 participants
High
Toxicity (≥ G3) · people with cutaneous melanoma
1 finding from 1 review
0.55 [0.31, 0.97]
1360 participants
Low
Time to complete healing · people with venous leg ulcers
Protease‐modulating matrix dressing regimen showed no clear difference in TIme to complete healing compared with any other dressing regimen (low certainty).
1 finding from 1 review
Proportion of participants with healed ulcers at 6 weeks · people with venous leg ulcers
It is very uncertain whether protease‐modulating matrix dressing regimen changes proportion of participants healed ‐ short term (4‐8 weeks) compared with any other dressing regimen (very low certainty).
1 finding from 1 review
Proportion of participants with healed ulcers at 12 weeks · people with venous leg ulcers
Protease‐modulating matrix dressing regimen showed no clear difference in proportion of participants healed ‐ medium term (12 weeks) compared with any other dressing regimen (low certainty).
1 finding from 1 review
Proportion of participants healed ‐ long term (over 24 weeks) · people with venous leg ulcers
Protease‐modulating matrix dressing regimen showed no clear difference in proportion of participants healed ‐ long term (over 24 weeks) compared with any other dressing regimen (low certainty).
1 finding from 1 review
Proportion of participants with 1 or more adverse events at 2‐12 weeks · people with venous leg ulcers
Protease‐modulating matrix dressing regimen showed no clear difference in proportion of participants with 1 or more adverse events at 2‐12 weeks compared with any other dressing regimen (low certainty).
1 finding from 1 review
Global State: clinically important improvement · patients with delusional disorder
The review found no eligible studies for this question.
1 finding from 1 review
Mental state: Delusions ‐ clinically significant improvement · patients with delusional disorder
The review found no eligible studies for this question.
1 finding from 1 review